Fig. 9.

Binding specificity of [⁸⁹Zr]ZrDFO-Amivantamab (0.37 MBq = 2.5 μg) in vivo determined by biodistribution studies at 4 days p.i in the MDA-MB-468 xenograft model, was evaluated 4 days p.i. (a) [⁸⁹Zr]ZrDFO-Amivantamab uptake in the tumor under baseline and blocking conditions with 20 mg/kg of Amivantamab, α-EGFR, or α-c-MET (n = 3 per group); (b) Comparison of tumor uptake among [⁸⁹Zr]ZrDFO-Amivantamab, [⁸⁹Zr]ZrDFO-α-EGFR and [⁸⁹Zr]ZrDFO-α-c-MET (n = 4 per group; * p < 0.05, ** p < 0.01)